# ENDONOVO THERAPEUTICS, INC.

ENDONOVO THERAPEUTICS, INC. is an Asset Manager based in Los Angeles, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Los Angeles, United States
- **Region:** North America
- **Address:** Los Angeles, CA, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** endonovo.com
- **LinkedIn:** https://www.linkedin.com/company/endonovo-therapeutics-inc

## Regulatory record

- **Reports private funds:** No

## About

Endonovo Therapeutics was organized in 2018 as a publicly traded company with Collier as its chairman and CEO, succeeding a prior entity that had traded on the OTC market. The firm does not operate as a traditional fund or family office. It is a micro-cap operating company that acquires and commercializes medical devices, functioning as a centralized vehicle for a single regenerative-medicine platform. Its history reflects the classic small-cap pivot: a former shell acquired an FDA-cleared asset and restructured the public entity around that one product. The firm's strategy centers on commercializing SofPulse, a pulsed electromagnetic field (PEMF) device cleared by the FDA for palliative treatment of post-operative pain and edema. Endonovo sells directly and through distributors to hospitals, clinics, and post-acute care facilities in the United States. The geographic footprint remains domestic, with distribution concentrated in North America. The company occasionally explores acquiring complementary non-invasive therapeutic devices, but its deployment to date has been a single-product build-out rather than a diversified portfolio approach. No recent closed-end fund raises or large-scale capital deployments are publicly recorded. The firm's scale is measured by its public-market capitalization and top-line device revenue rather than by assets under management or committed capital. In the last 24 months, Endonovo has focused on expanding SofPulse distribution agreements with regional medical-supply distributors and generating recurring consumable revenue from single-use treatment coils. The company does not operate a philanthropic foundation, a real-asset arm, or any disclosed club-investment vehicle. The firm's structural differentiator is its status as a publicly listed operating company in a space — evidence-based PEMF therapy — that is otherwise dominated by private medical-device startups and wellness-industry players. This gives family offices and institutional allocators a liquid, SEC-reporting vehicle for diligence on a single FDA-cleared device. The governance structure is led solely by Collier, concentrating strategic and operating authority in one principal, which is unusual relative to the typical multi-founder board structure of health-tech startups.

## Sectors

- Digital Health
- Healthcare Services
- Regenerative Medicine

## People

- Alan Collier — Chairman and Chief Executive Officer

## Questions

### What investment stages does Endonovo typically target?

The company targets FDA-cleared or late-clinical-stage therapeutic devices that can be commercialized through its existing distribution relationships. This is not a venture-capital stage strategy — it acquires assets that have completed the regulatory pathway and are ready for commercial scaling.

### Does Endonovo have meaningful recurring revenue from its device platform?

Yes. SofPulse generates recurring revenue from single-use disposable treatment coils that must be replaced for each therapy session. The hardware itself is sold as a capital-equipment unit, but the consumable coils create a razor-and-blade revenue model that the firm publicly emphasizes as a key economic differentiator.

### Which sectors does Endonovo explicitly avoid?

Pharmaceutical development, biologics, and surgical robotics are outside its disclosed scope. The firm's strategy is constrained to non-invasive, electroceutical devices that carry FDA clearances rather than approvals, focusing on pain management and inflammation reduction. It has not disclosed any interest in consumer wellness devices or unregulated therapeutic products.

## Related profiles

- [SB Technology Holdings](https://altss.com/profile/sb-technology-holdings-inc)
- [DSG Global](https://altss.com/profile/dsg-global-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/endonovo-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology